Eczema Market Epidemiology, Size, Trends, and Forecast 2024-2034
According to the IMARC Group, eczema market reached a value of US$ 16.8 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 37.1 Billion by 2034, exhibiting a growth rate (CAGR) of 7.46% during 2024-2034. This can be attributed to the emerging popularity of monoclonal antibodies, including rocatinlimab, for moderate to severe disease conditions, since they can enhance safety and lower toxicity among the population.
Eczema, also recognized as dermatitis, represents a common skin condition that causes inflammation and irritation of the skin. The eczema market is driven by several key factors, including the rising prevalence of the condition, growing awareness about its impact on quality of life, and advances in treatment options. Besides this, the increasing incidence of the illness, particularly among children and young adults, has spurred demand for pharmacological and non-pharmacological treatments, further augmenting the eczema market growth. With the condition often persisting into adulthood, there is also a growing market for long-term management options that address acute flare-ups and ongoing maintenance.
Moreover, pharmaceutical treatments, such as corticosteroids, calcineurin inhibitors, and biologics like dupilumab have seen widespread use, with biologics emerging as a key growth segment due to their ability to target specific pathways involved in inflammation, thereby catalyzing the eczema market expansion. In addition to prescription medications, over-the-counter topical treatments, including moisturizers and emollients, continue to dominate the market, owing to their role in managing mild to moderate conditions. Additionally, the increasing interest in personalized medicine is also influencing the eczema market growth, with advances in genetic and molecular research paving the way for more targeted and individualized therapies. Lifestyle and environmental factors, such as climate change and rising pollution, are contributing to the growing number of cases. Furthermore, the trend toward biologics and personalized treatment strategies, combined with greater awareness of the disease’s emotional and social impact, is expected to bolster the eczema market expansion in the coming years.
Request for a sample of this report: https://www.imarcgroup.com/eczema-market/requestsample
Countries Covered:
• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
Analysis Covered Across Each Country:
• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Eczema Market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Eczema Market
• Reimbursement scenario in the market
• In-market and pipeline drugs
This report also provides a detailed analysis of the current Eczema Market drugs and late-stage pipeline drugs.
In-Market Drugs:
• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
Late-Stage Pipeline Drugs:
• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance
Ask the Analyst for Customization and Explore the Full Report with TOC: https://www.imarcgroup.com/request?type=report&id=7537&flag=A
Competitive Landscape with key players:
The competitive landscape of the Eczema Market has been studied in the report with the detailed profiles of the key players operating in the market.
LEO Pharma
Novartis/Meda
Regeneron/Sanofi
Pfizer
AbbVie
Arcutis Inc
Kymab/Sanofi
Eli Lilly
selection
Kyowa Kirin
Browse other reports by IMARC Group
prader-willi syndrome market- https://www.imarcgroup.com/prader-willi-syndrome-market
polycystic kidney disease market- https://www.imarcgroup.com/polycystic-kidney-disease-market
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
EndFragment
